{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000039","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.590834+00:00","generated_at":"2026-06-15T03:48:29.917350+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis","bullets":["Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.","Cash and investments totaled $526.1M; reiterated cash runway through year-end 2026.","Completed $50M stock repurchase program authorized in January 2023.","Initiated global Phase 2b trial for ANB032 (BTLA agonist) in moderate-to-severe atopic dermatitis; top-line data expected by year-end 2024.","Plans to start Phase 2b trial for rosnilimab in rheumatoid arthritis in Q3 2023 and second Phase 2 trial by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000039","json":"https://secwatch.observer/filing/0001370053-23-000039.json","markdown":"https://secwatch.observer/filing/0001370053-23-000039.md","text":"https://secwatch.observer/filing/0001370053-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/0001370053-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/anab-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:48:29.917350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f696c126979ce33c8010fc8ed8ebd49d76f1c5f","claim":"ANAPTYSBIO, INC reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/0001370053-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}